- Recent Funding
- Investors
- Vivo Capital
Vivo Capital portfolio
Vivo Capital has 9 portfolio companies on record at Recent Funding, with 3 investments in the last 12 months.
About this page
It is a venture capital firm based in Palo Alto, US, founded in 1996. It led 2 of the 9 rounds it joined. Its most recent investment on record is Langlai Technology's Series B+ round in November 2026, alongside PICC Capital Investment Management, Qianhai Ark Capital, Changjiang Capital and 2 others. By category, its portfolio leans toward Health and bio (9) and Logistics and mobility (1). It has co-invested with Sixty Degree Capital, Pictet Alternative Advisors and Lilly Asia Ventures, most often Sixty Degree Capital (2 rounds).
About Vivo Capital
Fund returns
| Fund | Vintage | Size | Net IRR | TVPI | DPI | As of |
|---|---|---|---|---|---|---|
| Vivo Capital IX | 2019 | — | 18.8% | 1.73x | 0.70x | Jun 30, 2025 |
| Vivo Opportunity Fund, LP | 2018 | — | — | 1.84x | 1.84x | Mar 31, 2025 |
| Vivo Capital Fund VIII, L.P. | 2015 | — | 14.9% | 1.96x | 1.51x | Jun 30, 2025 |
| Vivo Capital Surplus Fund VIII, L.P. | 2015 | — | 15.9% | 2.01x | 1.55x | Jun 30, 2025 |
Funds raised
| Fund | Fund # | Size | Announced |
|---|---|---|---|
| III | $740M | Venture Capital Journal |
What Vivo Capital invests in
- Health and bio · 9 · 100%
- Logistics and mobility · 1 · 11%
- Manufacturing and industrial · 1 · 11%
- Education · 1 · 11%
Vivo Capital recent investments
| Company | Round | Date | Alongside |
|---|---|---|---|
| Series B+ | PICC Capital Investment Management (lead), Qianhai Ark Capital, Changjiang Capital +2 | ||
| Series B+ | Biospring Partners (lead), Bain Capital Life Sciences | ||
| Series B+ · $103M | Pictet Alternative Advisors, EQT Life Sciences, Forge Life Science Partners (lead) +6 | ||
| Series B+ | Marshall Wace, Janus Henderson Investors, Deep Track Capital +6 | ||
| Series B+ · $52M · lead | Pictet Alternative Advisors (lead), Longwood Fund, Johnson & Johnson Innovation +6 | ||
| Series A · $52M | Lilly Asia Ventures, CICC (lead), Kaitai Capital +6 | ||
| Series B+ · $50M · lead | The New York City Investment Fund, Dreavent 6, Novo Holdings +4 | ||
| Seed | Lilly Asia Ventures, Kaitai Capital |
How Vivo Capital invests
Vivo Capital portfolio companies
LLanglai TechnologySeries B+ · Nov 2026
SSeran BioscienceSeries B+ · Sep 2026
KKinaset Therapeutics$103MSeries B+ · Jan 2026
335PharmaSeries B+ · Nov 2024
PPulmocide$52MSeries B+ · Dec 2022
RRgenta Therapeutics$52MSeries A · Nov 2022
IInspirna$50MSeries B+ · Jul 2022
IImmune-Onc Therapeutics$73MSeries B+ · Mar 2021
OOricell Therapeuticsbacker
| Company | Round with Vivo Capital | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Series B+ | undisclosed | Nov 14, 2026 Series B+ |
Health and bio |
Series B+ | undisclosed | Sep 29, 2026 Series B+ |
Health and bio |
Series B+ · $103M | $143M | Jan 9, 2026 Series B+ |
Health and bio |
Series B+ | undisclosed | Nov 26, 2024 Series B+ |
Health and bio |
Series B+ · $52M · lead | $174.4M | Dec 6, 2022 Series B+ |
Health and bio |
Series A · $52M | $52M | Nov 3, 2026 Series B+ |
Health and bio |
Series B+ · $50M · lead | $50M | Jul 11, 2022 Series B+ |
Health and bio |
Series B+ · $73M | $211M | Jan 5, 2023 Series B+ |
Health and bio |
backer | $235M | Apr 10, 2026 round |
Most frequent co-investors
SSixty Degree Capital2 shared rounds · last Jan 9, 2026
PPictet Alternative Advisors2 shared rounds · last Jan 9, 2026
LLilly Asia Ventures2 shared rounds · last Nov 29, 2022
KKaitai Capital2 shared rounds · last Nov 29, 2022
PPICC Capital Investment Management1 shared round · last Nov 14, 2026
- QQianhai Ark Capital1 shared round · last Nov 14, 2026
CChangjiang Capital1 shared round · last Nov 14, 2026
GGF Qianhe Investment1 shared round · last Nov 14, 2026
CChina Merchants Venture1 shared round · last Nov 14, 2026
BBiospring Partners1 shared round · last Sep 29, 2026
BBain Capital Life Sciences1 shared round · last Sep 29, 2026
RRA Capital Management1 shared round · last Jan 9, 2026
Acquisitions
| Acquired company | Announced |
|---|---|
| · markets.financialcontent |
Similar investors
BBusiness Growth Fund9 companies · 4 deals in 12 mo
FFrazier Life Sciences9 companies · 4 deals in 12 mo
FFrist Cressey Ventures9 companies · 4 deals in 12 mo
LLegend Capital9 companies · 4 deals in 12 mo
TThe Venture Collective9 companies · 4 deals in 12 mo
TTown Hall Ventures9 companies · 3 deals in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Net returns as reported by the public-pension and foundation LPs invested in each fund.
Firm profile and fund returns: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.
Venture funds Vivo Capital raised, from the list of new VC funds compiled by Shai Goldman (Brex). Each size links to the article that states it, or to that list where no article was found. All new funds: new VC funds.
Share is of the 9 rounds on Recent Funding that name Vivo Capital. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists Vivo Capital, which is a subset of its real portfolio. API: /api/v1/investors/vivo-capital (get a free API key). More: the most active VC firms and new venture capital funds.
The week's top funded startups and market insights, in your inbox every Monday.
Unsubscribe anytime · privacy